You Are Here    Home   News

News
Infants in southern Africa start antiretroviral therapy late with advanced disease
by Lesley Odendal, 2014-10-21 09:50
Three quarters of infants starting antiretroviral therapy (ART) across eleven clinics in southern Africa had severe HIV disease and 87.2% met the 2006 World Health Organization (WHO) definition of severe immunosuppression, according to a study presented at the 2014 Southern African HIV Clinicians Society conference in Cape Town, South Africa, last month. There was a modest improvement

No to treating our way out of the epidemic, say South African experts
by Keith Alcorn, 2014-10-21 08:20
No, we cannot treat our way out of the HIV epidemic, was the resounding sentiment of a panel of expert clinicians and the audience, at a debate held at the 2014 Southern African HIV Clinicians Conference in Cape Town last month. Professor Richard Chaisson of the Johns Hopkins University School of Medicine argued that

No to treating our way out of the epidemic, say South African experts
by Lesley Odendal, 2014-10-21 08:20
No, we cannot treat our way out of the HIV epidemic, was the resounding sentiment of a panel of expert clinicians and the audience, at a debate held at the 2014 Southern African HIV Clinicians Conference in Cape Town last month. Professor Richard Chaisson of the Johns Hopkins University School of Medicine argued that

Sofosbuvir/ledipasvir safe and effective for genotype 1 HCV
by Liz Highleyman, 2014-10-20 18:30
A single-tablet regimen containing the hepatitis C virus (HCV) nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir - the combination in Gilead Science's recently approved Harvoni pill - was well-tolerated and cured 97% of patients with HCV genotype 1 in the Phase 3 ION trials, researchers reported at the IDWeek 2014 meeting earlier this month in Philadelphia. The advent of direct-acting antiviral agents has revolutionized treatment for chronic hepatitis C, especially with the long-awaited

Inflammatory markers associated with development of diabetes in people taking HIV therapy
by Michael Carter, 2014-10-20 10:00
Low-level elevations in important markers of systemic inflammation are associated with the development of type-2 diabetes in people taking antiretroviral therapy (ART), investigators report in the online edition of the Journal of Acquired Immune Deficiency Syndromes. The authors examined the relationship between baseline levels of high sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) and incident

High effectiveness seen in English PrEP trial
by Gus Cairns, 2014-10-16 13:00
The Steering Committee* of the PROUD trial of pre-exposure prophylaxis (PrEP) in gay men in England announced today that participants currently on the deferred arm of the study, who have not yet started PrEP, will be recalled to their clinics and offered the opportunity to begin PrEP ahead of schedule. This is because

Targeted adherence measures and viral load monitoring needed to improve retention in South African ART programme
by Lesley Odendal, 2014-10-16 09:00
57% of people living with HIV in South Africa who are eligible to initiate antiretroviral therapy (ART) are in care and only 37% of the 2012/2013 cohort of people receiving ART were given a viral load test, according to new results announced by the CEO of the South African National AIDS Council (SANAC) at

HIV stigma starts young, but can be corrected, African schoolchildren's study shows
by Gus Cairns, 2014-10-15 11:00
A study conducted among nearly 40,000 school students aged 12 to 14 in nine southern African countries shows that in some countries over a fifth of students would “avoid or shun” a friend who revealed they had HIV and that in three countries over a third of students believe that children living with